A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee

@inproceedings{DelgadoEnciso2018API,
  title={A phase I–II controlled randomized trial using a promising novel cell-free formulation for articular cartilage regeneration as treatment of severe osteoarthritis of the knee},
  author={Ivan Delgado-Enciso and Juan Paz-Garcia and Jose Valtierra-Alvarez and Jorge Preciado-Ramirez and Rom{\'a}n Almeida-Trinidad and Jos{\'e} Guzm{\'a}n-Esquivel and Martha A. Mendoza-Hernandez and A Garc{\'i}a-Vega and Alejandro D. Soriano-Hern{\'a}ndez and Jose L. Cortes-Bazan and H{\'e}ctor R. Galvan-Salazar and Ariana Cabrera-Licona and Iram P Rodr{\'i}guez-S{\'a}nchez and Margarita L Mart{\'i}nez-Fierro and Josuel Delgado-Enciso and Brenda Paz-Michel},
  booktitle={European journal of medical research},
  year={2018}
}
BACKGROUND A promising novel cell-free bioactive formulation for articular cartilage regeneration, called BIOF2, has recently been tested in pre-clinical trials. The aim of the present study was to evaluate the efficacy and safety of BIOF2 for intra-articular application in patients with severe osteoarthritis of the knee. METHODS A prospective, randomized, 3-arm, parallel group clinical trial was conducted. It included 24 patients with severe osteoarthritis of the knee (WOMAC score 65.9 ± 17… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

Similar Papers

Loading similar papers…